We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study.
- Authors
Tan, Khee Ming; Chia, Burton; Lim, Jing Quan; Khoo, Lay Poh; Cheng, Chee Leong; Tan, Leonard; Poon, Eileen; Somasundaram, Nagavalli; Farid, Mohamad; Tang, Tiffany Pooi Ling; Tao, Miriam; Cheah, Daryl Ming Zhe; Laurensia, Yurike; Pang, Jane Wan Lu; Song, Tammy; Tan, Jing; Huang, Dachuan; Kim, Seok Jin; Kim, Won Seog; Ong, Choon Kiat
- Abstract
Extranodal NK/T-cell lymphoma, nasal type (NKTL) is an aggressive type of non-Hodgkin lymphoma closely associated with Epstein-Barr virus and characterized by varying degrees of systemic inflammation. We aim to examine the prognostic significance of peripheral blood neutrophil-lymphocyte ratio (NLR) in patients with NKTL. Therefore, we conducted a retrospective review of 178 patients with biopsy-proven NKTL from the National Cancer Centre Singapore and Samsung Medical Center, South Korea. Using receiver operating curve analysis, an optimal cut-off for high NLR (>3.5) in predicting overall survival (OS) was derived. Survival analysis was performed using the Kaplan-Meier method and multivariable Cox proportional regression. In patients with high NLR, estimated 5-year OS was 25% compared to 53% in those with low NLR. In multivariable analysis, high NLR, in addition to age ≥60 years, presence of B-symptoms and stage III/IV at diagnosis, was independently correlated with worse OS (HR 2.08; 95% CI 1.36 to 3.18; p = 0.0008) and progression-free survival (HR 1.66; 95% CI 1.11 to 2.46; p = 0.0128). A new prognostic index (NABS score) derived from these factors stratified patients into low (0), low-intermediate (1), high-intermediate (2) and high (3–4) risk subgroups, which were associated with 5-year OS of 76.5%, 55.7%, 29.2% and 0% respectively. In conclusion, high NLR is an independent prognostic marker and the NABS model can be used to risk-stratify NKTL patients.
- Subjects
HODGKIN'S disease; T-cell lymphoma; KILLER cells; EPSTEIN-Barr virus; PROGRESSION-free survival
- Publication
Scientific Reports, 2019, Vol 9, Issue 1, pN.PAG
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-019-51522-0